Blood biomarker points to increased risk of brain metastasis in patients with inflammatory breast cancer

Researchers at The University of Texas MD Anderson Cancer Center have identified a targetable driver of brain metastases in patients with aggressive inflammatory breast cancer. The study uncovers a novel role for soluble E-cadherin (sEcad) in promoting tumor invasion while resisting cancer cell death and triggering brain inflammation via the CXCR2 signaling pathway.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup